Novel paradigm for immunotherapy of breast cancer by engaging prophylactic immunity against hepatitis B-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Novel paradigm for immunotherapy of breast cancer by engaging prophylactic immunity against hepatitis B

Published:2016-08-18 Issue:1 Volume:5 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical and Translational Medicine

Author:

Malecki Marek¹²³,Sabo Chelsea⁴,Foorohar Afsoon⁵,Tombokan Xenia⁶

Affiliation:

1. National Magnetic Resonance FacilityNational Institutes of HealthMadisonWIUSA

2. Phoenix Biomolecular Engineering FoundationSan FranciscoCAUSA

3. University of WisconsinMadisonWIUSA

4. Sutter Health CenterSan FranciscoCAUSA

5. University of SheffieldSheffieldUK

6. Bruker CorporationWoodlandsTXUSA

Funder

PBMEF

National Science Foundation

National Institutes of Health

Publisher

Wiley

Subject

Molecular Medicine,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1186/s40169-016-0111-8

Reference30 articles.

1. Global Cancer Incidence and Mortality Rates and Trends—An Update

2. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

3. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

4. Anti-p185HER2 monoclonal antibodies: Biological properties and potential for immunotherapy

5. Treatment of HER2-positive breast cancer

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-cancer effect of metformin on the metastasis and invasion of primary breast cancer cells through mediating NF-kB activity;Acta Histochemica;2021-05

2. Metformin promotes apoptosis in primary breast cancer cells by downregulation of cyclin D1 and upregulation of P53 through an AMPK-alpha independent mechanism;TURKISH JOURNAL OF MEDICAL SCIENCES;2021-04-30

3. Could hepatitis B vaccine act as an adjuvant to lower risk and relapses of cancer?;Clinical and Experimental Pharmacology and Physiology;2019-05-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3